Simomics is delighted to announce that the Innovative Medicines Initiative (IMI), a partnership funded by the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has officially launched the project “Prioritisation and Risk Evaluation of Medicines in the EnviRonment” (PREMIER) in September 2020.
The PREMIER project aims to deliver a novel assessment system for characterising the environmental risks of active pharmaceutical ingredients (APIs) and Simomics is the consortium partner tasked with developing this online platform.
We, at Simomics, are excited to work with top pharmaceutical companies, academics, research institutes and EU regulators over the next six years as part of this project consortium.
Active ingredients from medicines can enter the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). However, so far just a handful of the 1900 or so APIs in use have been assessed.
The PREMIER project aims to deliver a novel assessment system for characterising the environmental risks of APIs. This system will be used to prioritise and screen older (‘legacy’) APIs that have never been through an ERA. It will also be used to pick up potential environmental risks in new APIs that are still under development.
PREMIER also hopes its work will contribute to greener drug design in general, and help to make environmental data on APIs more visible and accessible to all stakeholders.
Simomics is leading Work Package 3 (ERA Database and Digital Assessment System), which involves developing a Database to store all the data relevant for Environmental Risk Assessments, and a Digital Assessment System (DAS) allowing stakeholders to query the database, run in-silico models, and perform risk assessments from a web-based platform.
The work builds on the strengths of Simomics and our previous Virtual Laboratory technologies, and we are the only for-profit SME in the consortium.
Simomics’ Database and DAS technologies will bring together the outputs from all other work packages from the project into one common online platform and we are proud to be developing the software system that will underpin the project.
PREMIER is an Innovative Medicines Initiative (IMI) project.
Simomics is part of a consortium with 25 European partners (including the European Medicines Agency) that is funded through Horizon 2020. Ten members of the consortium are industry partners who are self-funding. The overall project leader is Prof. Ad Ragas (Radboud University).
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N0 875508.
Find Out More
To learn more about the PREMIER project and partners, check out the project website, LinkedIn and Twitter accounts. For more information on the Simomics PREMIER digital assessment system, our other ecotoxicology and decision support tools and how we could help you, please contact us at firstname.lastname@example.org.